mRNA COVID Vaccination During Cancer Treatment Associated With Dramatic Survival Improvement
A major study reveals cancer patients receiving immune checkpoint inhibitors experienced significantly improved survival when vaccinated with mRNA COVID-19 vaccines. Researchers report vaccinated patients were approximately twice as likely to be alive three years later compared to unvaccinated counterparts. The findings suggest potential dual benefits from widely available vaccines.
Unexpected Survival Benefit Discovered
Cancer patients undergoing immunotherapy had double the three-year survival rate when they received at least one mRNA COVID-19 vaccine during treatment, according to a new study led by researchers from the University of Texas MD Anderson Cancer Center and the University of Florida’s McKnight Brain Institute. The research suggests commercially available COVID vaccines may provide significant benefits beyond viral protection for immunocompromised patients.
